Compare Biocon Ltd with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs IPCA LABS - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON IPCA LABS BIOCON /
IPCA LABS
 
P/E (TTM) x 31.5 40.6 77.5% View Chart
P/BV x 4.1 8.5 47.8% View Chart
Dividend Yield % 0.2 0.1 169.7%  

Financials

 BIOCON    IPCA LABS
EQUITY SHARE DATA
    BIOCON
Mar-19
IPCA LABS
Mar-19
BIOCON /
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs7071,042 67.9%   
Low Rs554590 93.8%   
Sales per share (Unadj.) Rs91.9298.6 30.8%  
Earnings per share (Unadj.) Rs16.735.0 47.7%  
Cash flow per share (Unadj.) Rs24.249.4 48.9%  
Dividends per share (Unadj.) Rs1.003.00 33.3%  
Dividend yield (eoy) %0.20.4 43.1%  
Book value per share (Unadj.) Rs101.6247.1 41.1%  
Shares outstanding (eoy) m600.00126.35 474.9%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x6.92.7 251.1%   
Avg P/E ratio x37.723.3 161.8%  
P/CF ratio (eoy) x26.116.5 158.0%  
Price / Book Value ratio x6.23.3 187.9%  
Dividend payout %6.08.6 69.8%   
Avg Mkt Cap Rs m378,330103,108 366.9%   
No. of employees `0006.113.4 45.6%   
Total wages/salary Rs m11,6537,874 148.0%   
Avg. sales/employee Rs Th8,994.32,807.0 320.4%   
Avg. wages/employee Rs Th1,900.7585.8 324.5%   
Avg. net profit/employee Rs Th1,635.3329.0 497.1%   
INCOME DATA
Net Sales Rs m55,14437,732 146.1%  
Other income Rs m1,444577 250.3%   
Total revenues Rs m56,58838,309 147.7%   
Gross profit Rs m15,8836,901 230.2%  
Depreciation Rs m4,4781,824 245.5%   
Interest Rs m709189 375.7%   
Profit before tax Rs m12,1405,465 222.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1231,042 203.7%   
Profit after tax Rs m10,0264,422 226.7%  
Gross profit margin %28.818.3 157.5%  
Effective tax rate %17.519.1 91.7%   
Net profit margin %18.211.7 155.1%  
BALANCE SHEET DATA
Current assets Rs m48,22823,778 202.8%   
Current liabilities Rs m30,37610,975 276.8%   
Net working cap to sales %32.433.9 95.4%  
Current ratio x1.62.2 73.3%  
Inventory Days Days68104 65.8%  
Debtors Days Days8666 129.7%  
Net fixed assets Rs m64,13020,368 314.9%   
Share capital Rs m3,000253 1,187.2%   
"Free" reserves Rs m57,98030,971 187.2%   
Net worth Rs m60,98031,224 195.3%   
Long term debt Rs m15,7661,409 1,119.3%   
Total assets Rs m121,92445,507 267.9%  
Interest coverage x18.130.0 60.5%   
Debt to equity ratio x0.30 573.1%  
Sales to assets ratio x0.50.8 54.5%   
Return on assets %8.810.1 86.9%  
Return on equity %16.414.2 116.1%  
Return on capital %16.817.3 96.7%  
Exports to sales %28.145.9 61.3%   
Imports to sales %18.916.6 113.5%   
Exports (fob) Rs m15,50617,308 89.6%   
Imports (cif) Rs m10,3996,266 165.9%   
Fx inflow Rs m15,50617,308 89.6%   
Fx outflow Rs m10,3996,266 165.9%   
Net fx Rs m5,10711,042 46.3%   
CASH FLOW
From Operations Rs m11,5464,923 234.5%  
From Investments Rs m-7,138-1,563 456.7%  
From Financial Activity Rs m-2,417-1,832 131.9%  
Net Cashflow Rs m2,1031,528 137.7%  

Share Holding

Indian Promoters % 40.4 45.9 88.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.4 73.7%  
FIIs % 10.7 25.3 42.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.4 114.4%  
Shareholders   109,995 36,892 298.2%  
Pledged promoter(s) holding % 0.0 2.1 1.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 142 Points Higher; Healthcare and Capital Goods Stocks Witness Buying(Closing)

Extending gains to the third straight day, Indian share markets witnessed buying interest throughout the day today, amid sustained foreign fund inflows and positive cues from global markets.

Related Views on News

STRIDES PHARMA SCIENCE Share Price Up by 15%; BSE HEALTHCARE Index Up 4.8% (Market Updates)

Aug 10, 2020 | Updated on Aug 10, 2020

STRIDES PHARMA SCIENCE share price is trading up by 15% and its current market price is Rs 616. The BSE HEALTHCARE is up by 4.8%. The top gainers in the BSE HEALTHCARE Index are STRIDES PHARMA SCIENCE (up 14.9%) and PFIZER (up 5.1%). The top losers are ALKEM LABORATORIES (down 0.1%) and FORTIS HEALTHCARE (down 0.3%).

LUPIN Share Price Up by 10%; BSE HEALTHCARE Index Up 4.9% (Market Updates)

Aug 10, 2020 | Updated on Aug 10, 2020

LUPIN share price is trading up by 10% and its current market price is Rs 978. The BSE HEALTHCARE is up by 4.9%. The top gainers in the BSE HEALTHCARE Index are LUPIN (up 10.5%) and DIVIS LABORATORIES (up 12.1%). The top losers are BLISS GVS PHARMA (down 0.4%) and DR. LAL PATHLABS LTD (down 1.0%).

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Stocks at 50% Off(Fast Profits Daily)

Aug 7, 2020

In this video I'll show you how to enter into a long trade at the right price.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Aug 10, 2020 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS